Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PLC Systems -- Ignore unavailable to you. Want to Upgrade?

To: Rob C. who wrote (1144)	9/30/1999 9:11:00 AM
From: Rob C.	Read Replies (2) \| Respond to of 1202

29 Sep 19:06 FRANKLIN, Mass. (Dow Jones)--PLC Systems Inc. (PLC) said a study published in The New England Journal of Medicine indicats that patients with severe angina have significantly improved outcomes following transmyocardial revascularization with its carbon dioxide, or CO2, heart laser. In a press release Wednesday, PLC Systems said results of the random, one-year, multicenter trial showed significantly reduced chest pain, improved quality of life and increased blood flow to the heart following the carbon dioxide laser treatment. The company said that each year, about 80,000 Americans develop severe coronory artery disease that cannot be treated by conventional techniques like bypass surgery or angioplasty. PLC Systems develops medical systems and technology. -Dorothea Degen; Dow Jones Newswires; 201-938-5400 (END) DOW JONES NEWS 09-29-99 07:06 PM Copyright 1999 Dow Jones & Company, Inc.